Phaarmasia Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Phaarmasia Ltd is ₹ 94.05 as of 12 May 15:30 . The P/E Ratio of Phaarmasia Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Phaarmasia Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Phaarmasia Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Phaarmasia Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Phaarmasia Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Phaarmasia Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Phaarmasia Ltd

Incorporated in 1981, Phaarmasia Limited is a manufacturing unit dedicated in manufacturing facility of Hormonal (Oral contraceptive tablets) and Combipack with Iron Tablet.
M/s Phaarmasia Limited Unit-II was established in 1993-94. The plant is situated in a hygienic environment; free from dust, smoke, chemical & biological emission.
Phaarmasia Ltd. Is an independent State-of-the-art-manufacturing unit having manufacturing facility of international standards with manufacturing capacity of more than 30 million units per annum. During the year 2000, the company became a Sick Industrial Company under SICA and therefore the same was referred to the BIFR. During past a few decades, Phaarmasia mastered and manufactured wide range of Pharmaceutical Formulations at a WHO-GMP certified and ISO 9001-certified manufacturing facility.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Phaarmasia Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Phaarmasia Ltd or Sanofi India Ltd?

Market cap of Phaarmasia Ltd is 64 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Phaarmasia Ltd and Sanofi India Ltd?

The stock performance of Phaarmasia Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Phaarmasia Ltd and Sanofi India Ltd?

As of May 12, 2026, the Phaarmasia Ltd stock price is INR ₹94.05. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Phaarmasia Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Phaarmasia Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.